Supporting this hypothesis, T2DM patients with preserved LVEF after SGLT2‐inhibitor therapy have been demonstrated to show improvement in absolute GLS (Russo et al., 2023), reinforcing the potential benefits of earlier intervention and glycemic management on cardiac function. Here, SLC5A2 is linked to type 2 diabetes mellitus.